- Home
- OVID vs LRMR Comparison
OVID vs LRMR Comparison
Compare OVID & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | LRMR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 455.8M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OVID | LRMR |
|---|---|---|
| Price | $2.26 | $3.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $4.60 | ★ $16.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.34 | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.29 | $2.26 |
| 52 Week High | $3.11 | $6.42 |
Technical Indicators
Market Signals| Indicator | OVID | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 48.97 |
| Support Level | $1.95 | $3.09 |
| Resistance Level | $2.38 | $3.74 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 14.97 | 76.26 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.